Diabetes mellitus represents one of the major epidemic concerns and hazard to global human health, since its incidence and prevalence have continued to increase in the past decades. The ADVANCE trial compared the effect of achieving a HbA1c target of 6.53%-7.29%: even though a significant reduction in renal events including new or worsening albuminuria was observed, this study also showed no evidence of reduction of major macrovascular events and rates of death. 11 Overall, these data suggest that caution should be taken when trying to achieve HbA1c targets below 7%, at least in patients with prior cardiovascular events. These studies also raised the question of what the HbA1c target should be in advanced CKD and ESRD patients. In fact, the mortality risk curve in maintenance dialysis patients clearly demonstrates a J shape, with ideal targets between 7% and 9%. 12 In fact, several studies have shown that HbA1c targets <6.5% and > 9% are associated with an increased risk for all causes mortality and macrovascular events in both patients with CKD and ESRD, concluding that HbA1c less than 7% should be avoided in chronic haemodialysis patients.
| EPIDEMI OLOGY OF D IAB E TE S AND DIABE TIC KIDNE Y DIS E A S E
Diabetes mellitus represents one of the major epidemic concerns and hazard to global human health, since its incidence and prevalence have continued to increase in the past decades. The International Diabetic Federation (IDF) recently published that in 2017 there were 425 million people worldwide with diabetes, with a projected rise to 629 million by 2045. 1 In the United States, it is estimated that 30.3 million people of all ages suffered from diabetes in 2015, representing 9.4% of the US population according to the 2017 National Diabetes Statistics Report. 2 Among different macrovascular and microvascular complications of diabetes, diabetic nephropathy or more broadly diabetic kidney disease (DKD) is defined by the presence of albuminuria (urinary albumin to creatinine ratio more than 30 mg/g) in two separate occasions three-month apart and/or sustained reduction in eGFR below 60 mL/min/1.73 m 2 and/or histological evidence of DKD on a kidney biopsy. DKD is the most common cause of ESRD and represents a strong independent risk factor for cardiovascular morbidity and mortality in patients with diabetes. 3, 4 Despite this, early diagnosis and management of DKD has remained inefficient, resulting in a rise to up to 94% in the number of deaths from the year 1990 to 2012 attributed to DKD, showing that prevention of DKD development and progression remains vastly unsuccessful. 5 
| RELE VAN CE OF HBA1C TARG E T FOR DK D DE VELOPMENT AND PROG RE SS I ON
Progression of DKD to ESRD can be delayed if glycaemic control is optimal with glycosylated haemoglobin (HbA1c) targets around 7.0%, as recommended by the American Diabetes Association (ADA). 6 The beneficial effects of targeting HbA1c on DKD onset has been undisputedly proven throughout several studies and trials including the Diabetes Control and Complications Trial, the United Kingdom Prospective Diabetes Study, the Veterans Affairs Diabetes
Trial and the Steno-2 Study, which all reported a correlation between achieved HbA1c targets and reduction of diabetic microvascular complications (diabetic retinopathy, neuropathy, and nephropathy). [7] [8] [9] [10] The inquiry of whether intensifying glycaemic control would provide additional benefits to microvascular and macrovascular events was assessed in the ACCORD and the ADVANCE trials. In the ACCORD trial, which recruited more than 10 thousand patients a third of which had prior cardiovascular events, the intensive therapy group targeting a HbA1c < 6% showed an increased rate of death of any cause (5.0% vs 4.0%; hazard ratio, 1.22; 95% CI: 1.01-1.46; P = 0.04) and increased mortality from cardiovascular causes (2.6% vs 1.8%; hazard ratio, 1.35; 95% CI: 1.04-1.76; P = 0.02) when compared with the standard therapy group aiming for HbA1c of 7.5%.
The ADVANCE trial compared the effect of achieving a HbA1c target of 6.53%-7.29%: even though a significant reduction in renal events including new or worsening albuminuria was observed, this study also showed no evidence of reduction of major macrovascular events and rates of death. 11 Overall, these data suggest that caution should be taken when trying to achieve HbA1c targets below 7%, at least in patients with prior cardiovascular events. These studies also raised the question of what the HbA1c target should be in advanced CKD and ESRD patients. In fact, the mortality risk curve in maintenance dialysis patients clearly demonstrates a J shape, with ideal targets between 7% and 9%. 12 In fact, several studies have shown that HbA1c targets <6.5% and > 9% are associated with an increased risk for all causes mortality and macrovascular events in both patients with CKD and ESRD, concluding that HbA1c less than 7% should be avoided in chronic haemodialysis patients.
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| ACCUR AC Y OF HBA1C DE TERMINATI ON IN ADVAN CED CKD AND E S RD
For patients that reach advanced DKD and ESRD, the accuracy of HbA1c measurements has been controversial. Many elements can contribute to falsely decreased reported levels of HbA1c, including the reduction of red blood cell lifespan, anaemia, malnutrition, blood transfusions, blood pH levels, iron supplementation and supplemental treatment with recombinant humanized erythropoietin, which are all often present in advanced DKD. 17 As a result, other markers of glycaemic control for patients in dialysis treatment have been suggested and some are currently under study, such as glycated albumin, glycosylated fructosamine, 1,5-anhydroglucitol and continuous glucose monitoring. 17 In several studies, glycated albumin has proved better association with macrovascular and microvascular disease as compared to HbA1c, and an even improved correlation with glycaemic status in patients with haemodialysis or peritoneal dialysis. On the other hand, fructosamine has proven to be as reliable as HbA1c in patients with haemodialysis and has been described as an accurate measurement in patients with controlled glucose levels. Finally, 1-5 anhydroglucitol has been proven to be an effective marker for diabetes risk and complications in patients that are not in CKD stages above 3, since its reabsorption is altered. Nonetheless, all of these markers are still under study and require more evidence
to determine the precise stages or window in which they can be either more or as accurate than HbA1c. 17 Although the ideal HbA1c target in CKD is still not well defined and the reliance of HbA1c measurements in these patients is ques- 23 Despite the fact that these agents are all effective in lowering HbA1c levels, their unique and individual effect on renal outcomes as well as their safety profile in patients with different stages of DKD has generated a lot of interest. 24 As many new agents have come on the market in the past few years, we will now review the safety and the HbA1c-independent beneficial effects on renal endpoints of different antihyperglycaemic agents. For each class of drugs, we will summarize the experimental data supporting specific renoprotective mechanism of each agent.
| IN SULIN S EN S ITIZER S
When looking at both patients with T1DM and T2DM, it is clear that insulin resistance correlates with and predicts albuminuria, suggesting a causative role of altered insulin receptor signalling in the pathogenesis of DKD. 25 Interestingly, insulin sensitizers of the class of thiazolidinediones have also suggested an additional renoprotective effect reducing albuminuria when compared to standard of care (even when achieving the same HbA1c targets). 26 More recently, the REMOVAL trial, although not designed to look at eGFR as primary outcome, suggested that addition of metformin in patients with T1DM already treated with insulin may confer a beneficial effect on the loss of eGFR observed at 36 months.
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If and how insulin sensitizers may directly protect the kidney has been investigated in the past few years. Among several cells of the glomerular filtration barrier, podocytes express all the elements of the insulin signalling cascade, and we and others have shown that glomerular and podocyte insulin resistance is already present at time of albuminuria onset.
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The mechanism by which altered insulin signalling may contribute to DKD remains unknown. While multiple pathways may be involved, 31, 32 we have clearly demonstrated that impaired lipid metabolism in glomerular cells is a key mediator of cellular insulin sensitivity and susceptibility to injury in DKD, as pharmacological reduction of cholesterol in podocytes is sufficient to prevent from the development of DKD and to restore insulin signalling. 33 Considerations about each specific insulin sensitizer are provided below.
| Metformin
Metformin hydrochloride is the preferred initial pharmacological agent used in all T2DM patients that failed lifestyle modifications recommended by the ADA guidelines and the European Association of Study of Diabetes if no contraindication is present. It is the favoured agent due to low cost, effectiveness, neutral impact on body weight and tolerability with minimal risk of hypoglycaemia. 34 Metformin reduces glycaemia primarily by inhibiting hepatic glucose production and enhancing insulin sensitivity in peripheral tissues; resulting in decreased endogenous glucose production and increasing glucose uptake. 35 Aside from its effect on glucose, metformin produces a pleiotropic effect through inhibition of the respiratory-chain complex 1 of the electron transport chain in the mitochondria through AMP-activated kinase (AMPK), known to regulate cellular metabolism, reducing the production of reactive oxygen species (ROS). 35 The drug's efficacy lowering haemoglobin HbA1c at the different available doses ranges from 0.9% to 2.0% reduction, at 500 mg/daily and 2000 mg/daily, respectively, with no hypoglycaemic events when used as monotherapy. Most common side effect is gastrointestinal intolerance such as diarrhoea. 36 A major concern is metformin-associated lactic acidosis, usually seen in ad- Mechanistically, the potential renoprotective effect of metformin has been linked with activation of the inhibitory effect mentioned previously in mitochondrial respiratory chain and reducing oxidative stress. 39, 40 Additional favourable effects include its weight neutrality by increasing satiation with potential weight loss effect, along with improvement in lipid profile, 38 which can both contribute to confer further renoprotection.
| Thiazolidinediones (TZDs)
TZDs are a group of antihyperglycaemic drugs that work by increasing insulin sensitivity in peripheral tissues, liver and adipose tissues potentiating insulin effect by acting as ligand of peroxisome-proliferator-activated receptors gamma (PPARγ), a nuclear receptor superfamily that regulates gene expression. 41 This group of agents are considered as second-line option or add-on treatment according to the ADA. 42 TZDs' efficacy in HbA1c reduction ranges from 1.0% to 1.5%. 43 Additionally to HbA1c reduction, TZDs may have a potential benefit preserving renal function in early stages of DKD and decreasing progression of albuminuria. 44, 45 These ameliorating effects in DKD are considered to be independent of the achieved HbA1c
and are thought to be secondary to decrease in oxidative stress and inflammation. 46 An advantage of TDZ drugs is that no dose adjustment is needed in the presence of advanced CKD or haemodialysis. Nevertheless, TZDs are associated with body weight gain (4.9 kg ± 4.5 kg, P < 0.01), extracellular fluid increase (1.2 L ± 0.2 L, P < 0.01) and increased incidence of heart failure (RR 1.33, 95% CI: 1.14-1.54). 47, 48 Because of this effect, they are contraindicated in New York Heart Association heart failure classes III and IV and cautious consideration with dose adjustment should be made in patients with mild heart failure. 49 
| INSULIN S ECRE TAGOG UE S
| Sulfonylureas
Sulfonylureas (SUs) were the first oral agents to treat T2DM and have been used for over 60 years. SUs work by stimulating the β-cells in the pancreas to increase insulin secretion and decreasing hepatic insulin clearance independently of hyperglycaemia. 50 SUs are recommended to be used after and in combination with metformin as dual therapy and frequently used due to low cost and high effectiveness.
Several studies have proven that SUs reduce HbA1C from 1.0% to 2.0% on average as monotherapy and combination, respectively. 51 SUs have a higher risk of hypoglycaemia in comparison with other oral antihyperglycaemic drugs and should be cautiously dosed in patients with DKD. 3 Since most SUs are eliminated by the kidneys, dose adjustment or drug discontinuation should be considered in advanced DKD stages. 3 Considering these facts, glipizide is the preferred 2nd generation SU as no dose adjustment is needed on moderate to severe CKD with no increased risk of hypoglycaemia.
Another commonly utilized agent, glyburide, should be avoided in CKD stages 3-5, while glimepiride can be used in CKD stage 3 with caution (Table 1) . 52 No evidence of renoprotective effects such as decreasing albuminuria or delaying DKD progression has been recognized as attributable to SUs. 53 The reports to be exposed in June 2019 of the CAROLINA trial will provide evidence of long-term outcomes of glimepiride vs linagliptin considering cardiovascular as primary and renal as secondary endpoints. 54 
| GLP-1 RAs
64,65
In terms of general adverse events, nausea, vomiting and diarrhoea are the most frequently reported and as such they can predispose to prerenal acute kidney injury. Nonetheless, a direct effect of GLP-1
RAs in protecting from kidney damage has not been established but is suggested by the evidence that GLP-1 RAs are highly expressed in the kidney.
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| Dipeptidyl peptidase 4 (DPP-4) inhibitors
In response to a meal, the half-life of GLP-1 is <2 minutes as it is quickly degraded by the DPP4 membrane glycoprotein, a wellknown catalytic protein with affinity to incretins as well as other substrates. 68 Therefore DPP-4 inhibitors were developed as novel oral glycaemic agents since they prolong GLP-1 half-life by modulating postprandial glucose, fasting blood glucose and ultimately decreasing HbA1C. DPP-4 inhibitors should be considered either as an alternative add-on in dual or triple therapy or as an alternative monotherapy treatment when metformin is contraindicated.
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Current FDA-approved DPP-4 inhibitors include sitagliptin, saxagliptin, alogliptin, linagliptin with a clinical efficacy in HbA1c reduction of 0.5% as monotherapy and increased effectiveness when used as dual therapy. 69 Aside from their efficacy, DPP-4 inhibitors exhibit multiple advantages when treating patients with T2DM.
These include a favourable tolerability with low risk for hypoglycaemia in individuals with advanced CKD, a neutral weight gain and an ability to reduce albuminuria. 69 In terms of renal effects, data from the cardiovascular outcomes trial SAVOR-TIMI 53 for saxagliptin showed a significant mean reduction in patients with urinary albumin/creatinine ratios (UACR) of renoprotective effects in long-term renal outcomes studies are yet to be determined. 70 Although the association between ACR levels and increased CV risk has been demonstrated previously, the potential beneficial relationship between the ACR reduction seen in this trail and its effect in CV risk in these patients was not determined. 70 For another commonly utilized agent, 360 patients with T2D, eGFR equal or above 30 mL/min/1.73 m 2 and UACR between 30
and 3000 mg/g were randomized to either receive linagliptin or placebo for 24 weeks in the MARLINA-T2D study. 71 At the end of the study, HbA1c below 7.0% was achieved by more individuals in the linagliptin group that in placebo: 36.2% compared to 9.3%, although the percentage change in UACR between these two had only a difference of 0.9%, proving to have an insignificant lowering effect in albuminuria, at least in the time frame of the study. 71 In the TECOS trial, which evaluated cardiovascular outcomes with sitagliptin, renal outcomes for patient with CKD stages 1-3b were evaluated over 4- 0.32-0.02 P = 0.032). Additionally, sitagliptin was not superior to placebo in cardiovascular outcomes. 72 Specifically for alogliptin, the EXAMINE trial demonstrated safety of alogliptin in terms of major adverse cardiac event in T2DM patients for a median of 17.5 months. Although the focus of the trial was not on renal outcomes, the overall safety profile of alogliptin was similar to placebo with no apparent differences in reduction of GFR, increase in blood creatinine, proteinuria and renal impairment (80% of general adverse events were reported in alogliptin vs 78.8% with placebo). 73 Another recent trial, CARMELINA, involved T2DM patients with high CV risk and kidney events including DKD. It analysed a total of 6979 patients randomized to either linagliptin or placebo for a median of 2.2 years.
In this study, linagliptin treatment resulted in a less frequent progression of albuminuria than placebo (35.3% vs 38.5%) (P < 0.03).
Sustained ESRD or death due to renal failure was not statistically different among groups (linagliptin 3.9% vs 4.4% placebo). 74 The ongoing phase 3 CAROLINA trial, which compares the effect of linagliptin to glimepiride on CV outcomes in T2DM, will shed further light on the efficacy of linagliptin on CV (primary) and renal (secondary) endpoints, which will be captured as transition in albuminuria classes. 74, 75 A significant reduction in albuminuria has also been observed in SAVOR-TIMI 53 trial and in smaller retrospective studies looking only at patients with macroalbuminuria (>300 mg/g). 75 Several (Table 1) . 78 
| Meglitinides
The most utilized agents in this family, repaglinide and nateglinide, share the same mechanism of action as SUs, as they bind to the sulfonylurea receptor in the beta cells of the pancreas but in a rather weaker manner and different place than SUs, resulting in a shorter effect in relation with time. 79 In terms of efficacy, repaglinide has shown to be superior to nateglinide decreasing HbA1C (1.5% vs 1.0%) with lower incidence of hypoglycaemic events. 80 In terms of safety, studies have focused mainly on the potential of meglitinides of causing hypoglycaemic events, where patients with DKD can present a 1.9-fold greater risk of developing hypoglycaemia compared to meglitinide nonusers. Among these agents, specifically repaglinide has reported higher incidence of hypoglycaemia compared to nateglinide in patients with type 2 diabetes (17.2% vs 6.1%). [81] [82] [83] Based on these results, KDOQI guidelines recommend starting nateglinide and repaglinide in a conservative manner, with doses of 60 mg for nateglinide and 0.5 mg in repaglinide for patients in CKD stage 4-5. 3 Neither experimental nor clinical studies have yet been designed to assess whether there is a direct impact of these agents on renal outcomes.
| G LYCOSURI C S
| SGLT-2 Inhibitors
Sodium glucose cotransporter-2 (SGLT2) inhibitors are the newest class of antihyperglycaemic drugs on the market, being first approved in 2013. These agents act on the sodium glucose cotransporter 2, which is in charge of reabsorbing glucose in the proximal tubular epithelial cells of the kidney. SGLT2 is located in the brush border of the S1 and S2 segments of the proximal tubule and it is in charge to reabsorb about 90% of glucose that is filtered through the glomerulus. 84 As a result, agents that inhibit this cotransporter specifically cause a decrease in the reabsorption of glucose in the proximal tubule and promote urinary glucose loss, creating a glucose-lowering effect that is independent of insulin. 85 Experimental studies strongly suggest that these agents may provide renoprotection through a hemodynamic mechanism that regulates tubuloglomerular feedback mediated by increase distal delivery of sodium, mechanism of action. 86 Irrespectively of the mechanism responsible for renoprotection, further studies are also needed to understand the reported decreased urinary excretion of ketone bodies in some patients, predisposing them to ketoacidosis. 85, 87, 88 Clinical studies focused on the efficacy of SGLT2 inhibitors have
shown an average decrease in HbA1c of 0.5%-0.9%. [88] [89] [90] [91] Adding SGLT2 inhibitors in patients receiving first-line monotherapy resulted in an increase proportion of subjects achieving a HbA1c <7%, with low risk of hypoglycaemic events. 90 In addition to glycaemic control, SGLT2 inhibitors cause a weight reduction of approximately 2 kg already at 6 weeks after initiation of therapy. 91, 92 The most common adverse events include urinary tract infections and vulvovaginitis/balanitis with higher incidence in female than male, which could be linked to an increase urinary glucose excretion and which may limit utilization of this drug in immunocompromised patients. 93 Efficacy of SGLT2 inhibitors is vastly dependent on GFR. Dapagliflozin has also been suggested to exert direct renoprotection. A randomized, double-blind, placebo-controlled study that included 252 patients with CKD stage 3A/B showed significant shifting to lower categories for albuminuria despite no significant difference in eGFR and HbA1c, strongly suggesting that renoprotection by SGLT2 inhibitors may strongly depend on eGFR. 100 Ongoing clinical trial evaluating the long-term effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with CKD (DAPA CKD) is expected completion in 2020. This trial is focused on the effect of this SGLT2-inhibitor compared to placebo on renal outcomes/ mortality and cardiovascular mortality in patients with CKD, with an estimated enrolment of 4000 participants. 101 Aside from cardiovascular and renal protection, this class of agents is also associated with a reduction of systolic and diastolic blood pressure of −4.0 mm Hg and −1.6 mm Hg, respectively.
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Other trials for SGLT2-inhibitors either recently finished or which remain to be finished for 2019-2020 include DAPA-HF, DECLARE-TIMI58, VERTIS-CV, EMPEROR-Preserved, and EMPEROR-reduced, all of them mostly focusing on cardiovascular outcomes. 103 
| INSULIN
As a result of the progressive loss of beta cell function observed in T2DM, or of failure to properly control HbA1c on oral agents, a certain amount of patients will require insulin therapy. 21 According to the ADA/European Association for the Study of Diabetes (EASD), initiation of treatment with insulin in patients on oral antihyperglycaemic agents could be required in patients with an HbA1c level of 9.0% or greater, and should be started above 10%. Once insulin is started, long-acting insulin is mostly the option, with a 10 U or 0.1-0.2 U/kg administration once daily with titration to achieve appropriate fasting blood glucose levels. This type of insulin can be added to any regimen, being safe and effective when administered in conjunction with metformin, GLP1-RA, SGLT-2 inhibitors, or pioglitazone. 22 Biphasic insulin twice a day has shown to be more efficacious achieving a HbA1C < 7%. This is however associated with greater prevalence of hypoglycaemic events and of weight gain. 22 Insulin dose adjustments are often required in patients with DKD. In fact, insulin clearance is highly dependent on GFR, and dose adjustment is necessary. Up to 50% reduction of total daily dose is recommended when eGFR falls between 10 and 50 mL/ 
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